Analytical Chemistry & Pharmacology

分析化学

• 批准号: 9316448
• 负责人: WILLIAM C ZAMBONI
• 金额: $ 10.53万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9316448
• 关键词: Analytical Chemistry; Antibody-drug conjugates; Antineoplastic Agents; Award; Biological; Biological Assay; Biological Products; Biology; Budgets; Cancer Center; Cancer Center Support Grant; Cancer Hospital; Cancer Immunology Science; Cellular biology; Chemicals; Clinical Pharmacology; Clinical Research; Clinical Trials Unit; Collaborations; Data; Data Analyses; Data Quality; Development; Drug Delivery Systems; Drug Kinetics; Early Therapeutic-Clinical Trials Network; Faculty; Funding; Future; Goals; Grant; Immunology; Institutes; Investigational Therapies; Mediating; Methodology; Methods; Modeling; Molecular; Nanotechnology; North Carolina; Patients; Peer Review; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenomics; Pharmacology; Pharmacology Shared Resource; Pharmacology Study; Pharmacy Schools; Phase; Pre-Clinical Model; Program Development; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resources; Sampling; Services; Therapeutic; Therapeutic Clinical Trial; Therapeutic Human Experimentation; Toxic effect; Translational Research; antitumor effect; cancer cell; clinical development; cost; cost effective; cost efficient; drug development; malignant breast neoplasm; member; model development; nanomedicine; nanoparticle; novel; novel anticancer drug; oncology; preclinical development; predicting response; programs; small molecule; translational research program; translational study; tumor

ABSTRACT- Analytical Chemistry and Pharmacology (ACP) Shared Resource The goals of the Analytical Chemistry and Pharmacology SR (ACP) are to support the translational development of small molecule, nanoparticle and biological anticancer agents via analytical chemistry and pharmacologic infrastructure, methodologies and expertise. The expansion of the Molecular Therapeutics Program, development of preclinical models to evaluate anticancer agents, the opening of the new North Carolina Cancer Hospital’s (NCCH) Clinical Trials Unit (CTU) and recruitment of additional faculty members to the UNC LCCC and Carolina Institute for NanoMedicine (CINM) created increased demand for applied and translational pharmacology services. This SR is comprised of the Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab and the sample processing lab located in the NCCH CTU. The SR develops and validates analytical assays in biological solutions, analyzes samples, performs pharmacokinetic and pharmacodynamic analyses of data for small molecule agents and provides specialized methods to evaluate the pharmacology of carrier-mediated agents (e.g. nanoparticle, conjugates, antibody drug conjugates) and biologics. The ACP supports studies throughout the UNC LCCC with extensive use by the Breast Cancer, Molecular Therapeutics, Cancer Cell Biology, Immunology and Clinical and Translational Research programs in the UNC LCCC. In addition, the ACP has significant collaborations with UNC LCCC members that are also part of the Carolina Institute for NanoMedicine (CINM), Carolina Center for Cancer Nanotechnology Excellence (C-CCNE) and the Center for Integrative Chemical Biology and Drug Discover (CICBDD), Center for Nanotechnology in Drug Delivery (CNDD) and the Center for Pharmacogenomics and Individualized Therapy (CPIT) in the UNC School of Pharmacy. The SR is currently being used by 14 investigators, 74% of whom are peer reviewed cancer center members. The total budget for the SR is $588,141 and $77,823 (13% of the total budget) is requested from the CCSG. Future plans are to expand the research of UNC LCCC members, develop novel pharmacologic methods and platforms and use the resources of this SR to recruit novel anticancer agents to UNC translational and clinical development.

摘要-分析化学和药理学 (ACP) 共享资源 分析化学和药理学 SR (ACP) 的目标是支持转化 通过分析化学和技术开发小分子、纳米粒子和生物抗癌剂 药理学基础设施、方法学和专业知识的扩展。 项目、开发临床前模型以评估抗癌药物、开辟新北 卡罗莱纳州癌症医院 (NCCH) 临床试验部门 (CTU) 并招募更多教职人员 北卡罗来纳大学 LCCC 和卡罗莱纳纳米医学研究所 (CINM) 增加了对应用和纳米医学的需求 该 SR 包括转化肿瘤学和纳米颗粒服务。 药物开发计划 (TOND2I) 实验室和样品处理实验室位于 NCCH CTU。 开发和验证生物溶液、胚胎样本的分析测定，执行药代动力学 和小分子药物数据的药效学分析，并提供专门的方法 评估载体介导的药物（例如纳米颗粒、缀合物、抗体药物）的药理学 ACP 支持整个 UNC LCCC 的研究，并被广泛使用。 乳腺癌、分子治疗、癌细胞生物学、免疫学以及临床和转化 此外，ACP 与 UNC LCCC 开展了重要合作。 也是卡罗莱纳纳米医学研究所 (CINM)、卡罗莱纳癌症中心的成员 纳米技术卓越中心 (C-CCNE) 以及综合化学生物学和药物发现中心 (CICBDD)、药物输送纳米技术中心 (CNDD) 和药物基因组学中心 北卡罗来纳大学药学院的个体化治疗 (CPIT) 目前有 14 名患者正在使用 SR。 研究人员，其中 74% 是同行评审的癌症中心成员 SR 的总预算为 向 CCSG 请求 588,141 美元和 77,823 美元（占总预算的 13%），未来的计划是扩大该项目。 北卡罗来纳大学 LCCC 成员的研究，开发新的药理学方法和平台并利用资源 该 SR 旨在招募新型抗癌药物进行 UNC 转化和临床开发。